Previous 10 | Next 10 |
CUPERTINO, Calif. , May 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced positive topline results from its Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. A total of 65 patients completed the stu...
DURECT Corporation ( DRRX ) is pursuing the use of POSIMIR (extended release bupivacaine solution) for post-operative pain and DUR-928, a sulfated oxysterol, for several indications. POSIMIR was in Phase 3 clinical trials in 2010, and an NDA was submitted in April, 2013. A Complete Response Le...
Image source: The Motley Fool. Durect Corp (NASDAQ: DRRX) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Shares of Durect (NASDAQ: DRRX) were up 23% at 1:53 p.m. EDT on Tuesday. The gains followed the release of first-quarter results after the closing bell Monday and disappointing trial results for Genfit (NASDAQ: GNFT) , a fellow biotech developing a potential competitor to Dure...
DURECT Corp (DRRX) Q1 2020 Earnings Conference Call May 11, 2020, 16:30 ET Company Participants Michael Arenberg - CFO & Secretary James Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development & Principal Scientist Conference Call ...
Durect (NASDAQ: DRRX ): Q1 GAAP EPS of -$0.05 misses by $0.02 . More news on: DURECT Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
CUPERTINO, Calif. , May 11, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2020 and provided a corporate update. Total revenues were $2.8 million and net loss was $9.9 million for the three months e...
CUPERTINO, Calif. , May 4, 2020 DURECT Corporation (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020. About DURECT Corporation DURECT is a biopharma...
DURECT Corporation ( DRRX ) is a speculative biotech that has a lot of long-term potential. I'm basing that on several promising programs from its pipeline. There is a near-term catalyst as it involves POSIMIR, which is being used to treat postoperative pain. The FDA is currently reviewing t...
The FDA has accepted for review a marketing application from privately held Innocoll Holdings Limited seeking approval of Xaracoll (bupivacaine hydrochloride collagen-matrix implants) for the management of postsurgical pain after inguinal (groin) hernia surgery. The agency's action date is...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...